Gri Bio, INC

GRI Bio announced that the U.S. FDA has granted Orphan Drug Designation to its investigational therapy GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

GRI Bio announced first quarter 2026 financial results, highlighting positive Phase 2a data for GRI-0621 in Idiopathic Pulmonary Fibrosis and progress on its pipeline.

GRI Bio reported full year 2025 financial results, a strengthened balance sheet with $8.2 million cash, and positive Phase 2a clinical data for its lead IPF program, GRI-0621.

GRI Bio announced additional positive Phase 2a clinical data for GRI-0621 in Idiopathic Pulmonary Fibrosis, demonstrating significant improvements in gene expression related to fibrosis and lung repair.

GRI Bio, Inc. announced a 1-for-28 reverse stock split to increase its per share trading price and regain Nasdaq listing compliance.

GRI Bio, Inc. announced it has conditionally regained compliance with Nasdaq's stockholders' equity requirement, avoiding potential delisting.

GRI Bio, Inc. (GRI) reported its first quarter 2026 financial results, highlighting progress in its clinical-stage biopharmaceutical development, particularly with its lead candidate GRI-0621 for fibrotic lung diseases.

GRI Bio reported increased net losses and a declining cash position, raising substantial doubt about its ability to continue as a going concern, despite progress in clinical trials and recent capital raises.

GRI Bio reports increased net losses and a going concern warning, despite recent capital raises and progress in its lead clinical program.

GRI Bio, Inc. announces its financial results for the first quarter of 2025, highlighting ongoing clinical trials for GRI-0621 and efforts to secure additional funding.

GRI Bio, a clinical-stage biopharmaceutical company, announced its financial results for the third quarter of 2024, highlighting ongoing clinical trial progress and recent financing activities.

GRI Bio, a clinical-stage biopharmaceutical company, announced its financial results for the second quarter of 2024, highlighting progress in its clinical programs and recent financing activities.

GRI Bio, Inc. announced positive topline results from its Phase 2a clinical trial for GRI-0621 in Idiopathic Pulmonary Fibrosis (IPF), while also disclosing substantial doubt about its ability to continue as a going concern.

GRI Bio, a clinical-stage biopharmaceutical company, details its financial performance for 2024 and outlines key developments in its pipeline, including its lead candidate GRI-0621 for IPF.

GRI Bio, Inc. released its 10-K filing, detailing clinical trial advancements for GRI-0621 and GRI-0803, alongside its financial status and future funding needs.

GRI Bio, Inc.'s Chief Financial Officer, Leanne Kelly, was granted 43,222 stock options with an exercise price of $1.93.

GRI Bio, Inc. Director David Leslie Szekeres was granted 39,897 stock options with an exercise price of $1.93, vesting over one year.

GRI Bio, Inc. Director David Charles Baker was granted 23,605 stock options with an exercise price of $1.93, vesting over one year.

GRI Bio, Inc. Director Camilla V Simpson received a grant of 23,605 stock options with an exercise price of $1.93, vesting over one year.

Vipin Chaturvedi, Chief Scientific Officer of GRI Bio, Inc., reports the acquisition of stock options.

GRI Bio, Inc. Director Roelof Rongen was granted 23,605 stock options with an exercise price of $1.93, vesting over one year.

GRI Bio, Inc. is seeking stockholder approval for a reverse stock split to address Nasdaq listing deficiencies and avoid potential delisting.

GRI Bio, Inc. announced its 2025 Annual Meeting of Stockholders will be held virtually on August 13, 2025, seeking approval for director elections, auditor ratification, and a significant increase in shares available for its equity incentive plan.

GRI Bio is asking stockholders to approve a reverse stock split to meet Nasdaq's minimum bid price requirement and avoid potential delisting.

GRI Bio, Inc. adjourned its Annual Meeting to September 6, 2024, to solicit additional proxies for the remaining proposals.

GRI Bio adjourned its Annual Meeting to September 6, 2024, to solicit additional proxies for remaining proposals after confirming the adjournment proposal was approved and a quorum was present.

GRI Bio, Inc. has engaged Campaign Management, LLC to solicit proxies for its upcoming Annual Meeting of Stockholders on August 23, 2024.

GRI Bio, Inc. amended its engagement agreement with H.C. Wainwright & Co., LLC, extending the term for capital raising activities and removing the right of first refusal.

GRI Bio, Inc. announces a new public offering of common stock and warrants to raise up to $10 million, alongside positive topline Phase 2a clinical trial results for its lead IPF candidate, GRI-0621, despite ongoing financial challenges and Nasdaq non-compliance.

GRI Bio launches a public offering of common stock and warrants, aiming to raise capital for its clinical-stage biopharmaceutical initiatives.

GRI Bio, Inc. unveils a public offering of common stock and warrants to fuel its clinical-stage biopharmaceutical endeavors.

GRI Bio is launching a public offering to sell shares of common stock, pre-funded warrants, and accompanying warrants to raise capital for working capital, product development, and general corporate purposes.

GRI Bio aims to raise capital to fund operations and development through a public offering of common stock, pre-funded warrants, and accompanying warrants.

Reporting Persons disclose beneficial ownership of 90,475 shares of GRI Bio, Inc. common stock, representing 5.9% of the class.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 9.99% beneficial ownership stake in GRI Bio, Inc. common stock.

Lincoln Alternative Strategies LLC has filed an amended Schedule 13G, reporting zero beneficial ownership in GRO Bio, Inc. common stock.

Lincoln Alternative Strategies LLC has reported a passive beneficial ownership of 11.83% in GRI Bio, Inc., holding 1,197,755 shares of common stock.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 9.99% beneficial ownership stake in GRI Bio, Inc. following a recent Securities Purchase Agreement.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a beneficial ownership of 4.99% in GRI Bio, Inc.'s common stock, totaling 40,261 shares, as reported in a recent Schedule 13G filing.